PEG drugs: an overview (Q34328580)

1 August 2017

1 reference

title

PEG drugs: an overview (English)

1 reference

1 August 2017

Greenwald RB

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

Journal of Controlled Release

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

issue

1-3

1 reference

1 August 2017

page(s)

159-171

1 reference

A branched monomethoxypoly(ethylene glycol) for protein modification

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

On the suitability of urethane bonds between the carrier and the drug moiety in poly(ethyleneglycol)-based oligomeric prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Prodrugs. Do they have advantages in clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

A novel connector linkage applicable in prodrug design

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

20-O-acylcamptothecin derivatives: evidence for lactone stabilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Prodrug Strategies Based on Intramolecular Cyclization Reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Design of intramolecularly activated prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Detection and characterization of antibodies to PEG-IFN-alpha2b using surface plasmon resonance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

PEG thiazolidine-2-thione, a novel reagent for facile protein modification: conjugation of bovine hemoglobin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-3659%2801%2900331-5

7 January 2021

10.1016/S0168-3659(01)00331-5

Identifiers

DOI

1 reference

1 August 2017

1 reference